Role of peroxisome proliferator-activated receptor γ and its ligands in the control of immune responses

Critical Reviews in Immunology

Volumn 23, Issue 1-2, 2003, Pages 1-13

  Nencioni, Alessio ^a   Wesselborg, Sebastian ^a   Brossart, Peter ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Apoptosis; Cyclopentenone prostaglandins; Dendritic cells; Lymphocytes; Tolerance

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIGEN; ANTINEOPLASTIC AGENT; CELL NUCLEUS RECEPTOR; CYCLOPENTENONE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; LIGAND; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN; PROSTAGLANDIN J2; ROSIGLITAZONE; TROGLITAZONE;

APOPTOSIS; BONE MARROW; CELL ACTIVATION; CELL SURVIVAL; DENDRITIC CELL; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; LYMPHOCYTE; LYMPHOID TISSUE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; THYMUS; WOUND HEALING;

ANIMALS; B-LYMPHOCYTES; DENDRITIC CELLS; HUMANS; INFLAMMATION MEDIATORS; LIGANDS; PROSTAGLANDINS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSCRIPTION FACTORS;

EID: 0038116167     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevImmunol.v23.i12.10     Document Type: Review

References (94)

1. Banchereau, J., and Steinman, R. M., Dendritic cells and the control of immunity. Nature 1998; 392:245-252.
2. Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y. J., Pulendran, B., and Palucka, K., Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18:767-811.
3. Brossart, P., Wirths, S., Brugger, W., and Kanz, L., Dendritic cells in cancer vaccines. Exp Hematol 2001; 29:1247-1255.
4. Heath, W. R., and Carbone, F. R., Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 2001; 19:47-64.
5. Lanzavecchia, A., and Sallusto, F., Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells. Science 2000; 290:92-97.
6. Krammer, P. H., CD95's deadly mission in the immune system. Nature 2000; 407:789-795.
7. Kurts, C., Heath, W. R., Carbone, F. R., Allison, J., Miller, J. F., and Kosaka, H., Constitutive class I-restricted exogenous presentation of self antigens in vivo. J Exp Med 1996; 184:923-930.
8. Refaeli, Y., Van Parijs, L., and Abbas, A. K., Genetic models of abnormal apoptosis in lymphocytes. Immunol Rev 1999; 169:273-282.
9. Clark, R. B., Bishop-Bailey, D., Estrada-Hernandez, T., Hla, T., Puddington, L., and Padula, S. J., The nuclear receptor PPAR γ and immunoregulation: PPARγ mediates inhibition of helper T cell responses. J Immunol 2000; 164:1364-1371.
10. Harris, S. G., and Phipps, R. P., The nuclear receptor PPAR γ is expressed by mouse T lymphocytes and PPAR γ agonists induce apoptosis. Eur J Immunol 2001; 31:1098-1105.
11. 2 induces IL-8 production in human T cells by a mitogen-activated protein kinase pathway. J Immunol 2002; 168:1372-1379.
12. 2, and peroxisome proliferator activated receptor-γ agonists induce apoptosis in transformed, but not normal, human T lineage cells. Immunology 2002; 105:23-34.
13. Wang, Y. L., Frauwirth, K. A., Rangwala, S. M., Lazar, M. A., and Thompson, C. B., Thiazolidinedione activation of peroxisome proliferator-activated receptor γ can enhance mitochondrial potential and promote cell survival. J Biol Chem 2002; 277:31781-31788.
14. Yang, X. Y., Wang, L. H., Chen, T., Hodge, D. R., Resau, J. H., DaSilva, L., and Farrar, W. L., Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor γ (PPARγ) agonists. PPARγ co-association with transcription factor NFAT. J Biol Chem 2000; 275:4541-4544.
15. Yang, X. Y., Wang, L. H., Mihalic, K., Xiao, W., Chen, T., Li, P., Wahl, L. M., and Farrar, W. L., Interleukin (IL)-4 indirectly suppresses IL-2 production by human T lymphocytes via peroxisome proliferator-activated receptor γ activated by macrophage-derived 12/15-lipoxygenase ligands. J Biol Chem 2002; 277:3973-3978.
16. Setoguchi, K., Misaki, Y., Terauchi, Y., Yamauchi, T., Kawahata, K., Kadowaki, T., and Yamamoto, K., Peroxisome proliferator-activated receptor-γ haploin-sufficiency enhances B cell proliferative responses and exacerbates experimentally induced arthritis. J Clin Invest 2001; 108:1667-1675.
17. 2 induce apoptosis in normal and malignant B-lineage cells. J Immunol 2000; 165:6941-6948.
18. Padilla, J., Leung, E., and Phipps, R. P. Human B lymphocytes and B lymphomas express PPAR-γ and are killed by PPAR-γ agonists. Clin Immunol 2002; 103:22-33.
19. Miyazaki, Y., Tachibana, H., and Yamada, K., Inhibitory effect of peroxisome proliferator-activated receptor-γ ligands on the expression of IgE heavy chain germline transcripts in the human B cell line DND39. Biochem Biophys Res Commun 2002; 295:547-552.
20. Faveeuw, C., Fougeray, S., Angeli, V., Fontaine, J., Chinetti, G., Gosset, P., Delerive, P., Maliszewski, C., Capron, M., Staels, B., Moser, M., and Trottein, F., Peroxisome proliferator-activated receptor γ activators inhibit interleukin-12 production in murine dendritic cells. FEBS Lett 2000; 486:261-266.
21. Gosset, P., Charbonnier, A. S., Delerive, P., Fontaine, J., Staels, B., Pestel, J., Tonnel, A. B., and Trottein, F., Peroxisome proliferator-activated receptor γ activators affect the maturation of human monocyte-derived dendritic cells. Eur J Immunol 2001; 31:2857-2865.
22. Nencioni, A., Grunebach, F., Zobywlaski, A., Denzlinger, C., Brugger, W., and Brossart, P., Dendritic cell immunogenicity is regulated by peroxisome proliferator-activated receptor γ. J Immunol 2002; 169:1228-1235.
23. Nencioni, A., Lauber, K., Grunebach, F., Brugger, W., Denzlinger, C., Wesselborg, S., and Brossart, P., Cyclopentenone prostaglandins induce caspase activation and apoptosis in dendritic cells by a PPAR-γ-independent mechanism: regulation by inflammatory and T cell-derived stimuli. Exp Hematol 2002; 30:1020-1028.
24. Desvergne, B., and Wahli, W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20:649-688.
25. Kersten, S., Desvergne, B., and Wahli, W., Roles of PPARs in health and disease. Nature 2000; 405:421-424.
26. Murphy, G. J., and Holder, J. C., PPAR-γ agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci 2000; 21:469-474.
27. Nwankwo, J. O., and Robbins, M. E., Peroxisome proliferator-activated receptor-γ expression in human malignant and normal brain, breast and prostate-derived cells. Prostaglandins Leukot Essent Fatty Acids 2001; 64:241-245.
28. Greene, M. E., Blumberg, B., McBride, O. W., Yi, H. F., Kronquist, K., Kwan, K., Hsieh, L., Greene, G., and Nimer, S. D., Isolation of the human peroxisome proliferator activated receptor γ cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr 1995; 4:281-299.
29. Jiang, C., Ting, A. T., and Seed, B., PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391:82-86.
30. Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., and Glass, C. K., The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998; 391:79-82.
31. Huang, J. T., Welch, J. S., Ricote, M., Binder, C. J., Willson, T. M., Kelly, C., Witztum, J. L., Funk, C. D., Conrad, D., Glass, C. K., Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase. Nature 1999; 400:378-382.
32. 2 production is likely antigen-presenting cells. Localization of glutathione-requiring prostaglandin D synthetase in histiocytes, dendritic, and Kupffer cells in various rat tissues. J Immunol 1989; 143:2982-2989.
33. 2 formation and characterization of its synthetases in various tissues of adult rats. Arch Biochem Biophys 1988; 260:521-531.
34. 2 metabolite generated during inflammatory processes. J Biol Chem 2002; 277:10459-10466.
35. Spanbroek, R., Hildner, M., Kohler, A., Muller, A., Zintl, F., Kuhn, H., Radmark, O., Samuelsson, B., and Habenicht, A. J., IL-4 determines eicosanoid formation in dendritic cells by down-regulation of 5-lipoxygenase and up-regulation of 15-lipoxygenase 1 expression. Proc Natl Acad Sci U S A 2001; 98:5152-5157.
36. Chawla, A., Barak, Y., Nagy, L., Liao, D., Tontonoz, P., and Evans, R. M., PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001; 7:48-52.
37. Moore, K.J., Rosen, E. D., Fitzgerald, M. L., Randow, F., Andersson, L. P., Altshuler, D., Milstone, D. S., Mortensen, R. M., Spiegelman, B. M., and Freeman M. W., The role of PPAR-γ in macrophage differentiation and cholesterol uptake. Nat Med 2001; 7:41-47.
38. Rubartelli, A., Poggi, A., and Zocchi, M. R., The selective engulfment of apoptotic bodies by dendritic cells is mediated by the alpha(v)beta3 integrin and requires intracellular and extracellular calcium. Eur J Immunol 1997; 27:1893-1900.
39. Girnun, G. D., Domann, F. E., Moore, S. A., and Robbins, M. E., Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter. Mol Endocrinol 2002; 16:2793-2801.
40. 2 is a ligand for the adipocyte determination factor PPARγ. Cell 1995; 83:803-812.
41. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 1995; 83:813-819.
42. 2. J Biol Chem 1983; 258:11713-11718.
43. Lehmann, J. M., Lenhard, J. M., Oliver, B. B., Ringold, G. M., and Kliewer, S. A., Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997; 272:3406-3410.
44. Gilroy, D. W., Colville-Nash, P. R., Willis, D., Chivers, J., Paul-Clark, M. J., and Willoughby, D. A., Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 1999; 5:698-701.
45. Willoughby, D. A., Moore, A. R., and Colville-Nash, P. R., Cyclopentenone prostaglandins - new allies in the war on inflammation. Nat Med 2000; 6:137-138.
46. Straus, D. S., and Glass, C. K., Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev 2001; 21:185-210.
47. Mullally, J. E., Moos, P.J., Edes, K., and Fitzpatrick, F. A., Cyclopentenone prostaglandins of the J series inhibit the ubiquitin isopeptidase activity of the proteasome pathway. J Biol Chem 2001; 276:30366-30373.
48. 2 inhibition of NF-κB-DNA binding through covalent modification of the p50 subunit. J Biol Chem 2001; 276:35530-35536.
49. Rossi, A., Kapahi, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M., and Santoro, M. G., Antiinflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature 2000; 403:103-108.
50. 2 inhibits multiple steps in the NF-κB signaling pathway. Proc Natl Acad Sci U S A 2000; 97:4844-4849.
51. 2 induces apoptosis of human hepatic myofibroblasts. A pathway involving oxidative stress independently of peroxisome-proliferator-activated receptors. J Biol Chem 2001; 276:38152-39158.
52. Kondo, M., Oya-Ito, T., Kumagai, T., Osawa, T., and Uchida, K., Cyclopentenone prostaglandins as potential inducers of intracellular oxidative stress. J Biol Chem 2001; 276:12076-12083.
53. Hortelano, S., Castrillo, A., Alvarez, A. M., and Bosca, L., Contribution of cyclopentenone prostaglandins to the resolution of inflammation through the potentiation of apoptosis in activated macrophages. J Immunol 2000; 165:6525-6531.
54. Rao, A., Luo, C., and Hogan, P. G., Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 1997; 15:707-747.
55. 2 and its metabolites induce caspase-dependent granulocyte apoptosis that is mediated via inhibition of IκBα degradation using a peroxisome proliferator-activated receptor-γ-independent mechanism. J Immunol 2002; 168:6232-6243.
56. 2 inhibits CX3CL1/fractalkine expression in human endothelial cells. Immunol Cell Biol 2002; 80:531-536.
57. Bazan, J. F., Bacon, K. B., Hardiman, G., Wang, W., Soo, K., Rossi, D., Greaves, D. R., Zlotnik, A., and Schall, T. J., A new class of membrane-bound chemokine with a CX3C motif. Nature 1997; 385:640-644.
58. Imai, T., Hieshima, K., Haskell, C., Baba, M., Nagira, M., Nishimura, M., Kakizaki, M., Takagi, S., Nomiyama, H., Schall, T. J., Yoshie, O., Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997; 91:521-530.
59. Shappell, S. B., Gupta, R. A., Manning, S., Whitehead, R., Boeglin, W. E., Schneider, C., Case, T., Price, J., Jack, G. S., Wheeler, T. M., Matusik, R. J., Brash A. R., and Dubois, R. N., 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res 2001; 61:497-503.
60. Brown, M. A., and Hural, J., Functions of IL-4 and control of its expression. Crit Rev Immunol 1997; 17:1-32.
61. + regulatory T cells. Curr Opin Immunol 2001; 13:644-649.
62. Caamano, J., Alexander, J., Craig, L., Bravo, R., and Hunter, C. A., The NF-kappa B family member RelB is required for innate and adaptive immunity to Toxoplasma gondii. J Immunol 1999; 163:4453-4461.
63. Zhou, J., Zhang, J., Lichtenheld, M. G., and Meadows, G. G., A role for NF-kappa B activation in perforin expression of NK cells upon IL-2 receptor signaling. J Immunol 2002; 169:1319-1325.
64. Albert, M. L., Jegathesan, M., and Darnell, R. B., Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells. Nat Immunol 2001; 2:1010-1017.
65. Weih, F., Carrasco, D., Durham, S. K., Barton, D. S., Rizzo, C. A., Ryseck, R. P., Lira, S. A., and Bravo, R., Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-κB/Rel family. Cell 1995; 80:331-340.
66. Burkly, L., Hession, C., Ogata, L., Reilly, C., Marconi, L. A., Olson, D., Tizard, R., Cate, R., and Lo, D., Expression of relB is required for the development of thymic medulla and dendritic cells. Nature 1995; 373:531-536.
67. Ashany, D., Savir, A., Bhardway, N., and Elkon, K. B., Dendritic cells are resistant to apoptosis through the Fas (CD95/APO-1) pathway. J Immunol 1999; 163:5303-5311.
68. L and resistance to CD95-mediated apoptosis of monocyte-derived dendritic cells: inhibition by bisindolylmaleimide. Blood 2000; 95:3478-3482.
69. Sallusto, F., and Lanzavecchia, A., Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus Interleukin 4 and down-regulated by tumor necrosis factor α. J Exp Med 1994; 179:1109-1118.
70. Zelle-Rieser, C., Ramoner, R., Artner-Dworzak, E., Casari, A., Bartsch, G., and Thurnher, M., Human monocyte-derived dendritic cells are deficient in prostaglandin E2 production. FEBS Lett 2002; 511:123-126.
71. Thurnher, M., Zelle-Rieser, C., Ramoner, R., Bartsch, G., and Holtl, L., The disabled dendritic cell. FASEB J 2001; 15:1054-1061.
72. Li, Q., and Verma, I. M., NF-κB regulation in the immune system. Nat Rev Immunol 2002; 2:725-734.
73. Ghosh, S., and Karin, M., Missing pieces in the NF-κB puzzle. Cell 2002; 109 Suppl:S81-96.
74. Chinetti, G., Griglio, S., Antonucci, M., Torra, I. P., Delerive, P., Majd, Z., Fruchart, J. C., Chapman, J., Najib, J., and Staels, B., Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophage. J Biol Chem 1998; 273:25573-25580.
75. Chung, S. W., Kang, B. Y., Kim, S. H., Pak, Y. K., Cho, D., Trinchieri, G., and Kim, T. S., Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-γ and nuclear factor-κB. J Biol Chem 2000; 275:32681-32687.
76. Subbaramaiah, K., Lin, D. T., Hart, J. C., and Dannenberg, A J., Peroxisome proliferator-activated receptor γ ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300. J Biol Chem 2001; 276:12440-12448.
77. Tang, G., Minemoto, Y., Dibling, B., Purcell, N. H., Li, Z., Karin, M., and Lin, A., Inhibition of JNK activation through NF-κB target genes. Nature 2001; 414:313-317.
78. Wang, C. Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V., and Baldwin, A. S. Jr., NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998; 281:1680-1683.
79. Yang, T. T., Xiong, Q., Enslen, H., Davis, R.J., and Chow, C. W., Phosphorylation of NFATc4 by p38 mitogen-activated protein kinases. Mol Cell Biol 2002; 22:3892-3904.
80. Wang, N., Verna, L., Chen, N. G., Chen, J., Li, H., Forman, B. M., and Stemerman, M. B., Constitutive activation of peroxisome proliferator-activated receptor-γ suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells. J Biol Chem 2002; 277:34176-34181.
81. Barak, Y., Nelson, M. C., Ong, E. S., Jones, Y. Z., Ruiz-Lozano, P., Chien, K. R., Koder, A., and Evans, R. M., PPAR γ is required for placental, cardiac, and adipose tissue development. Mol Cell 1999; 4:585-595.
82. Desreumaux, P., Dubuquoy, L., Nutten, S., Peuchmaur, M., Englaro, W., Schoonjans, K., Derijard, B., Desvergne, B., Wahli, W., Chambon, P., Leibowitz, M. D., Colombel, J. F., and Auwerx, J., Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor γ (PPARγ) heterodimer. A basis for new therapeutic strategies. J Exp Med 2001; 193:827-838.
83. 2 induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest 2000; 106:189-197.
84. 2 attenuates the development of acute and chronic inflammation. Mol Pharmacol 2002; 61:997-1007.
85. Su, C. G., Wen, X., Bailey, S. T., Jiang, W., Rangwala, S. M., Keilbaugh, S. A., Flanigan, A., Murthy, S., Lazar, M. A., and Wu, G.D., A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response. J Clin Invest 1999; 104:383-389.
86. Tanaka, T., Kohno, H., Yoshitani, S., Takashima, S., Okumura, A., Murakami, A., and Hosokawa, M., Ligands for peroxisome proliferator-activated receptors α and γ inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res 2001; 61:2424-2428.
87. 2 ameliorates experimental autoimmune encephalomyelitis. J Immunol 2002; 168:2508-2515.
88. Lewis, J. D., Lichtenstein, G. R., Stein, R. B., Deren, J. J., Judge, T. A., Fogt, F., Furth, E. E., Demissie, E. J., Hurd, L. B., Su, C. G., Keilbaugh, S. A., Lazar, M. A., and Wu, G. D., An open-label trial of the PPAR-γ ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol 2001; 96:3323-3328.
89. Dubuquoy, L., Dharancy, S., Nutten, S., Pettersson, S., Auwerx, J., and Desreumaux, P., Role of peroxisome proliferator-activated receptor γ and retinoid X receptor heterodimer in hepatogastroenterological diseases. Lancet 2002; 60:1410-1418.
90. Palakurthi, S. S., Aktas, H., Grubissich, L. M., Mortensen, R. M., and Halperin, J. A., Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor γ and mediated by inhibition of translation initiation. Cancer Res 2001; 61:6213-6218.
91. Goke, R., Goke, A., Goke, B., and Chen, Y., Regulation of TRAIL-induced apoptosis by transcription factors. Cell Immunol 2000; 201:77-82.
92. Nicholson, D. W., From bench to clinic with apoptosis-based therapeutic agents. Nature 2000; 407:810-816.
93. Goke, R., Goke, A., Goke, B., El-Deiry, W. S., and Chen, Y., Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL-induced apoptosis by induction of p21waf1/cip1. Digestion 2001; 64:75-80.
94. Kim Y, Suh N, Sporn M, Reed JC. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J Biol Chem 2002 Jun 21; 277(25):22320-22329.